Get the Stockscreener App
37.00
6.94%
-2.76
After Hours:
37.29
0.29
+0.78%
Kodiak Sciences Inc stock is traded at $37.00, with a volume of 5.25M.
It is down -6.94% in the last 24 hours and up +38.06% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
See More
Previous Close:
$39.76
Open:
$41.89
24h Volume:
5.25M
Relative Volume:
5.25
Market Cap:
$2.26B
Revenue:
-
Net Income/Loss:
$-217.34M
P/E Ratio:
-8.9832
EPS:
-4.1188
Net Cash Flow:
$-127.29M
1W Performance:
+66.29%
1M Performance:
+38.06%
6M Performance:
+134.18%
1Y Performance:
+1,109%
1-Day Range:
$36.91
$45.60
1-Week Range:
$21.00
$45.60
52-Week Range:
$1.92
$45.60
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
37.00 | 2.43B | 0 | -217.34M | -127.29M | -4.1188 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 115.27B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 80.00B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 43.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 43.52B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 30.74B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Kodiak Sciences: A Promising Breakthrough in Diabetic Retinopathy Trials - timothysykes.com
Kodiak Sciences (NASDAQ:KOD) Shares Gap Up After Analyst Upgrade - MarketBeat
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate - TradingView
Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $80.00 - MarketBeat
Kodiak Sciences: Shares Up On Positive Eye Disease DataBut I Remain On Sidelines (KOD) - seekingalpha.com
Why Kodiak Sciences Stock Is Suddenly Surging - TipRanks
Kodiak Sciences Inc. (NASDAQ:KOD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
How Kodiak Sciences Stock Rises To $120? - Yahoo Finance
Kodiak Sciences’ Zenkuda Shows Strong Phase 3 GLOW2 Results - TipRanks
Kodiak Sciences (NASDAQ:KOD) Earns Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright raises Kodiak Sciences stock price target on trial data - Investing.com
Kodiak Sciences reports positive Phase 3 GLOW2 results; Zenkuda shows 62.5% ≥2‑step DRSS vs 3.3% sham - TradingView
Kodiak Sciences reports positive GLOW2 trial results for Zenkuda By Investing.com - Investing.com South Africa
Kodiak Sciences (KOD) Climbs 75% on Stellar Clinical Results - Insider Monkey
Meta, Kodiak Sciences, Unity Software, Lumentum Holdings and Reddit: Why these 5 stocks are on investors' radars today - msn.com
META, KOD, U, LITE, RDDT: 5 Trending Stocks TodayMeta Platforms (NASDAQ:META) - Benzinga
Kodiak Sciences (KOD) Stock Surges as Zenkuda Eye Treatment Achieves Phase 3 Success - mexc.co
Kodiak Sciences shares soar after eye drug succeeds in late-stage study - msn.com
Recent Developments Propel Kodiak Sciences’ Stock Northwards - timothysykes.com
Kodiak’s Zenkuda sparkles in Glow2, BLA filing next - BioWorld MedTech
Kodiak Sciences stock hits 52-week highhere's why - msn.com
Kodiak Sciences shares climb over 71% after strong late-stage trial results for eye drug Zenkuda - msn.com
Kodiak Sciences price target raised to $56 from $39 at Jefferies - TipRanks
Kodiak Sciences Up Over 74%, on Pace for Record Percent Increase -- Data Talk - Moomoo
Kodiak Sciences (NASDAQ:KOD) Sets New 12-Month HighHere's What Happened - MarketBeat
Traders Buy High Volume of Kodiak Sciences Put Options (NASDAQ:KOD) - MarketBeat
Kodiak Sciences stock soars over 60%: what’s behind the sharp rally - Invezz
Second positive Phase III results for Kodiak’s Zenkuda - The Pharma Letter
Crude Oil Gains 4%; Commercial Metals Posts Mixed Q2 Results - Benzinga
Kodiak Sciences (KOD) Stock Jumps After Eye Drug Passes Major Trial - MEXC
Kodiak Sciences Stock Hits 52-Week HighHere's Why - Benzinga
Morning Movers: Kodiak Sciences skyrockets following GLOW2 study results - TipRanks
US Stocks: Kodiak Sciences shares soar 68% after eye drug succeeds in late-stage study - The Economic Times
Kodiak Sciences stock hits 52-week high at $35.43 - Investing.com
Kodiak Sciences Soars 68%: A Turbulent Rally That Defies Industry Trends - bitget.com
Kodiak Sciences stock hits 52-week high at $35.43 By Investing.com - Investing.com India
Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday - Benzinga
Dow Falls 250 Points; US Initial Jobless Claims Rise - Benzinga
Jefferies Financial, MillerKnoll dip premarket; Kodiak Sciences surges - Investing.com
Kodiak Sciences shares surge after eye drug succeeds in late-stage study - msn.com
KOD: Promising Phase 3 Results for Zenkuda in Diabetic Retinopat - gurufocus.com
Jefferies Financial, MillerKnoll dip premarket; Kodiak Sciences surges By Investing.com - Investing.com Australia
Kodiak Sciences (KOD) Surges on Positive Phase 3 Trial Results f - gurufocus.com
Kodiak Sciences reports GLOW2 study of Zenkuda met primary endpoint - TipRanks
Kodiak climbs on late-stage trial win for diabetic retinopathy therapy - MSN
Kodiak Sciences Shares Climb on Positive Late-Stage Trial Results - 富途牛牛
Kodiak Sciences stock surges on positive trial results By Investing.com - Investing.com India
Kodiak Sciences' Zenkuda Therapy Achieves Key Milestones in Phase 3 Trial - Intellectia AI
Kodiak Sciences stock surges on positive trial results - Investing.com
Kodiak posts trial win for diabetic retinopathy drug (KOD) - seekingalpha.com
Kodiak Sciences reports positive GLOW2 trial results for Zenkuda - Investing.com
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kodiak Sciences Inc Stock (KOD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BORGESON JOHN A. | See Remarks |
Jun 17 '25 |
Sale |
3.65 |
723 |
2,640 |
183,316 |
3.03%
2.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):